Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trial.

S, Hoffmann; E, Schrezenmeier; M, Desmarets; F, Halleck; A, Durrbach; L, Peters; AT, Tremmel; A, Seidel; M, Führer; F, Bachmann; J, Schrezenmeier; J, Greiner; S, Körper; H, Hofmann; C, Ludwig; C, Vieweg; B, Jahrsdörfer; K, Budde; M, Schmidt; J, Münch; N, Joher; E, Daguindau; B, Grüner; G, Brunotte; C, Vauchy; E, Seifried; D, Bradshaw; LJ, Estcourt; DJ, Roberts; E, Toussirot; B, Rijnders; P, Tiberghien; H, Schrezenmeier

doi:10.1016/j.ebiom.2025.105613

Public

Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trial.

Shared by NobleBlocks on Feb 27, 2025 • 12:00 AM UTC

Authors:

Hoffmann S

Schrezenmeier E

Desmarets M

Abstract

Background COVID-19 convalescent plasma (CCP) is a treatment option for COVID-19. This study investigated the safety and efficacy of early, very high-titre CCP in immunocompromised individuals with mild COVID-19.Methods This randomised, controlled, open-label trial assessed CCP in immunocompromised ...

Subject

Randomised Trial

Neutralising Antibody

Convalescent Plasma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!